Gilead 3Q Revenues: $2.4 billion (+14%) 3Q Earnings: $675.5 million (-9%) YTD Revenues: $7.1 billion (+15%) YTD Earnings: $1.8 billion (-14%) Comments: Antiviral product sales increased 13% to $2.0 billion. Atripla sales increased 9% to $865.4 million. Sales of Truvada increased 8% to $804.2 million. Sales of Viread increased 11% to $214.9 million. Sales of Complera/Eviplera grew more than fivefold to $99.3 million. Sales of Stribild, which launched in the U.S. in August 2012, were $17.5 mi...